Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 54

Similar articles for PubMed (Select 20528633)

1.

Contemporary management of patients with Type 2 diabetes.

McAdam-Marx C, Gaebler JA, Bellows BK, Brixner DI.

Expert Rev Cardiovasc Ther. 2010 Jun;8(6):767-70. doi: 10.1586/erc.10.62.

PMID:
20528633
2.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
3.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
4.

Inhibition of glucagon secretion.

Young A.

Adv Pharmacol. 2005;52:151-71. Review.

PMID:
16492545
5.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
6.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD.

Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. Epub 2007 Apr 16.

PMID:
17599422
7.

Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction.

Mafong DD, Henry RR.

Curr Atheroscler Rep. 2008 Feb;10(1):55-60. Review.

PMID:
18366986
8.

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG.

Curr Med Res Opin. 2008 Jan;24(1):275-86.

PMID:
18053320
9.

Hypoglycemia-associated autonomic failure in advanced type 2 diabetes.

Segel SA, Paramore DS, Cryer PE.

Diabetes. 2002 Mar;51(3):724-33.

11.

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group.

Ann Intern Med. 2005 Oct 18;143(8):559-69.

PMID:
16230722
12.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
14.
15.

Exenatide: new drug. Type 2 diabetes for some overweight patients.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):228-31.

PMID:
18087791
16.

Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting.

Bhushan R, Elkind-Hirsch KE, Bhushan M, Butler WJ, Duncan K, Marrioneaux O.

Diabetes Technol Ther. 2009 Jun;11(6):353-9. doi: 10.1089/dia.2008.0090.

PMID:
19459763
17.
18.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

19.

How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.

Steiner G.

Cardiovasc Drugs Ther. 2009 Oct;23(5):403-8. doi: 10.1007/s10557-009-6190-7. Review.

PMID:
19757004
20.

A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes.

Rothman RL, Malone R, Bryant B, Shintani AK, Crigler B, Dewalt DA, Dittus RS, Weinberger M, Pignone MP.

Am J Med. 2005 Mar;118(3):276-84.

PMID:
15745726
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk